Pharmaceutical ERA•Regulatory Toxicology•PDE / OEL
[email protected]
Permitted Daily Exposure / ADE

Home→PDE Profiles → Abacavir→

Abacavir Permitted Daily Exposure (PDE) / ADE

General class/use (background only): Nucleoside analogue reverse transcriptase inhibitor used with other antiretroviral medicines in HIV treatment. The applicable product label defines the authorised use. Specific authorised uses depend on the applicable product label and jurisdiction. PubChem source.

Project-specific PDE/ADE report support for health-based exposure-limit setting and risk identification in pharmaceutical manufacturing.

CAS Registry Number
136470-78-5
Molecular formula
C14H18N6O
Molecular weight
286.33 g/mol

Related pharmaceutical form(s) (name only): Abacavir sulfate. Its identifiers are not merged into the main identity; confirm exact substance form before assessment use.

View request basketPrefer email? [email protected]
Hazard reviewPoint of departureAdjustment factors
About this profile

Scope of the Abacavir PDE/ADE assessment

This ToxWriter profile covers the scope for a project-specific Abacavir PDE report. PDE means Permitted Daily Exposure; ADE means Acceptable Daily Exposure. The final assessment scope depends on intended use, route, available pharmacological and toxicological evidence, and regulatory context.

Typical scientific scope

  • Pharmacological and toxicological hazard review relevant to the intended health-based limit.
  • Identification of critical effects and a scientifically justified point of departure.
  • Assessment-factor and uncertainty considerations, with rationale for relevant modifiers.
  • Clinical data and route-to-route considerations where they materially affect the exposure limit.
Scope noteThis page outlines ToxWriter’s PDE/ADE assessment support for Abacavir. Project-specific data, calculations and conclusions are supplied within the agreed report scope.
Intended use

Health-based exposure limit documentation.

PDE / ADE assessments can support risk identification for residual active substances, including shared-facility and cleaning/carryover contexts.

PDE/ADE is a daily exposure threshold; it is not an occupational airborne OEL.

PDE / ADE framework
PDE / ADE background →EMA health-based exposure limits (HBEL) guidelineICH Q3C(R9) · residual solventsICH Q3D(R2) · elemental impuritiesICH Q3A(R2) · drug-substance impuritiesICH Q3B(R2) · drug-product impuritiesICH M7(R2) · mutagenic impurities

These documents cover different parts of pharmaceutical quality, impurities and health-based exposure-limit practice. They are general references and do not establish a substance-specific PDE for Abacavir.

ERAPDE / ADEOEL / OEB
Further reading

Published scientific article

A selected published review by Varun Ahuja and Mohan Krishnappa provides scientific background relevant to permitted daily exposure limit derivation. It does not replace applicable regulatory guidance or a substance-specific assessment.